Skip to main content
. Author manuscript; available in PMC: 2012 Oct 18.
Published in final edited form as: Cancer Cell. 2011 Oct 18;20(4):487–499. doi: 10.1016/j.ccr.2011.09.004

Figure 8. SIRT2 Gene Expression in Human Cancers.

Figure 8

(A) Comparison of SIRT2 protein levels revealed by tissue array in 36 pairs of primary breast cancers and adjacent normal breast tissues, as well as 9 pairs of lymph node metastatic infiltrating ductal carcinomas and cancer adjacent normal lymph node tissues (adj. normal). Levels of SIRT2 staining were classified as high (Hi), medium (Me), low (Lo), and negative (No).

(B) Examples of immunohistochemical images of 3 primary cancers (1: No; 2: Lo, 3: Me), 1 lymph node metastatic infiltrating ductal carcinoma (4: No), and 2 adjacent normal breast tissues (5: Lo; 6: Hi). Scale bars = 10 μm.

(C–D) SIRT2 expression levels from microarray data of 264 HCC samples (C), presented as raw log2 ratio (tumor/normal: T/N) (D). Red represents high ratio of T/N and green represents low ratio of T/N.

(E) Real-time RT-PCR of 10 pairs of samples was also presented. Data shown is average ±SD.

(F) A model illustrating actions of SIRT2 in regulating APC/C activity through deacetylation of CDH1 and CDC20, which is critical for maintaining normal mitosis. SIRT2 deficiency impairs APC/C activity, leading to mitotic catastrophe, genetic instability, and tumorigenesis.

(See also Figure S7)